Advertisement
Advertisement

DMAC

DMAC logo

DiaMedica Therapeutics Inc. Common Stock

8.04
USD
Sponsored
-0.43
-5.11%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

8.04

+0.01
+0.10%

DMAC Earnings Reports

Positive Surprise Ratio

DMAC beat 20 of 28 last estimates.

71%

Next Report

Date of Next Report
Mar 16, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.18
Implied change from Q3 25 (Revenue/ EPS)
--
/
+5.88%
Implied change from Q4 24 (Revenue/ EPS)
--
/
--

DiaMedica Therapeutics Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, DMAC reported earnings of -0.17 USD per share (EPS) for Q3 25, missing the estimate of -0.16 USD, resulting in a -4.17% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -14.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.18 USD, with revenue projected to reach -- USD, implying an increase of 5.88% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, DiaMedica Therapeutics Inc. Common Stock reported EPS of -$0.17, missing estimates by -4.17%, and revenue of $0.00, 0% as expectations.
The stock price moved down -14.1%, changed from $6.31 before the earnings release to $5.42 the day after.
The next earning report is scheduled for Mar 16, 2026.
Based on 6 analysts, DiaMedica Therapeutics Inc. Common Stock is expected to report EPS of -$0.18 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement